{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Modeling - RAG\n",
    "\n",
    "This notebook include testing of some models until we defined the final one.\n",
    "\n",
    "Let's remember the strategies:\n",
    "\n",
    "1. Extractive QA: The answer is a span of text from the context.\n",
    "    1. In this case we can possible use some kind of retriever in the query and use the model as an extractor for the context. \n",
    "    2. The problem with this (at this point) is don't know how good each topic of the dataset is represented in the dataset.\n",
    "2. Open Generative QA: The answer generated by one of the retrieved options.\n",
    "    1. Using more complexity (in terms of memory and time) we can use a model to generate the answer. We rely in some pre-trained model knowledge better approach some queries variants.\n",
    "    2. More complexity, more inference time, possible need GPU and not can generate no safety answer (considering the dataset is composed only by true/safe answers).\n",
    "3. Generative QA: The answer is a free text.\n",
    "    1. The same as the open generative QA but not always rely in the retrieved options.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Libs and Variables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "import logging\n",
    "import random\n",
    "import re\n",
    "import warnings\n",
    "\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import torch\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.document_loaders import DataFrameLoader\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "from langchain_ollama import OllamaEmbeddings\n",
    "from langchain_ollama import OllamaLLM\n",
    "from langchain_ollama import ChatOllama\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.prompts.chat import ChatPromptTemplate\n",
    "from langchain_core.prompts.prompt import PromptTemplate\n",
    "from metrics import compute_metrics\n",
    "from sklearn.model_selection import train_test_split\n",
    "from tqdm.notebook import tqdm\n",
    "\n",
    "# Remove pandas warning from Sentence Transformers lib\n",
    "warnings.simplefilter(action=\"ignore\", category=FutureWarning)\n",
    "\n",
    "# Ollama http logs\n",
    "logging.getLogger(\"httpx\").setLevel(logging.WARNING)\n",
    "\n",
    "clean_repeated_ws = lambda text: re.sub(r\"\\s+\", \" \", text).strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "def seed_all():\n",
    "    \"\"\"\n",
    "    Seed all the random number generators to ensure reproducibility.\n",
    "\n",
    "    This function sets the seed for the Python built-in random module and the NumPy random module to 42.\n",
    "    This ensures that any random operations performed using these modules will produce the same results\n",
    "    each time the code is run.\n",
    "    \"\"\"\n",
    "    random.seed(42)\n",
    "    np.random.seed(42)\n",
    "    torch.manual_seed(42)\n",
    "\n",
    "\n",
    "seed_all()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "DATA_PATH = \"../data/data.csv\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_csv(DATA_PATH)\n",
    "\n",
    "data[\"question\"] = data[\"question\"].astype(str)\n",
    "data[\"answer\"] = data[\"answer\"].astype(str)\n",
    "\n",
    "data[\"question\"] = data[\"question\"].apply(clean_repeated_ws)\n",
    "data[\"answer\"] = data[\"answer\"].apply(clean_repeated_ws)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "</style>\n",
       "<table id=\"T_38729\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_38729_level0_col0\" class=\"col_heading level0 col0\" >question</th>\n",
       "      <th id=\"T_38729_level0_col1\" class=\"col_heading level0 col1\" >answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_38729_level0_row0\" class=\"row_heading level0 row0\" >0</th>\n",
       "      <td id=\"T_38729_row0_col0\" class=\"data row0 col0\" >What is (are) Glaucoma ?</td>\n",
       "      <td id=\"T_38729_row0_col1\" class=\"data row0 col1\" >Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. The most common form of the disease is open-angle glaucoma. With early treatment, you can often protect your eyes against serious vision loss. (Watch the video to learn more about glaucoma. To enlarge the video, click the brackets in the lower right-hand corner. To reduce the video, press the Escape (Esc) button on your keyboard.) See this graphic for a quick overview of glaucoma, including how many people it affects, whos at risk, what to do if you have it, and how to learn more. See a glossary of glaucoma terms.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_38729_level0_row1\" class=\"row_heading level0 row1\" >1</th>\n",
       "      <td id=\"T_38729_row1_col0\" class=\"data row1 col0\" >What is (are) Glaucoma ?</td>\n",
       "      <td id=\"T_38729_row1_col1\" class=\"data row1 col1\" >The optic nerve is a bundle of more than 1 million nerve fibers. It connects the retina to the brain.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_38729_level0_row2\" class=\"row_heading level0 row2\" >2</th>\n",
       "      <td id=\"T_38729_row2_col0\" class=\"data row2 col0\" >What is (are) Glaucoma ?</td>\n",
       "      <td id=\"T_38729_row2_col1\" class=\"data row2 col1\" >Open-angle glaucoma is the most common form of glaucoma. In the normal eye, the clear fluid leaves the anterior chamber at the open angle where the cornea and iris meet. When the fluid reaches the angle, it flows through a spongy meshwork, like a drain, and leaves the eye. Sometimes, when the fluid reaches the angle, it passes too slowly through the meshwork drain, causing the pressure inside the eye to build. If the pressure damages the optic nerve, open-angle glaucoma -- and vision loss -- may result.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_38729_level0_row3\" class=\"row_heading level0 row3\" >3</th>\n",
       "      <td id=\"T_38729_row3_col0\" class=\"data row3 col0\" >Who is at risk for Glaucoma? ?</td>\n",
       "      <td id=\"T_38729_row3_col1\" class=\"data row3 col1\" >Anyone can develop glaucoma. Some people are at higher risk than others. They include - African-Americans over age 40 - everyone over age 60, especially Hispanics/Latinos - people with a family history of glaucoma. African-Americans over age 40 everyone over age 60, especially Hispanics/Latinos people with a family history of glaucoma. See this graphic for a quick overview of glaucoma, including how many people it affects, whos at risk, what to do if you have it, and how to learn more.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_38729_level0_row4\" class=\"row_heading level0 row4\" >4</th>\n",
       "      <td id=\"T_38729_row4_col0\" class=\"data row4 col0\" >How to prevent Glaucoma ?</td>\n",
       "      <td id=\"T_38729_row4_col1\" class=\"data row4 col1\" >At this time, we do not know how to prevent glaucoma. However, studies have shown that the early detection and treatment of glaucoma, before it causes major vision loss, is the best way to control the disease. So, if you fall into one of the higher risk groups for the disease, make sure to have a comprehensive dilated eye exam at least once every one to two years. Get tips on finding an eye care professional. Learn what a comprehensive dilated eye exam involves.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x1e7fab97970>"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.head(5).style"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Data split"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "# DEVELOPMENT\n",
    "data = data.head(10000)\n",
    "\n",
    "# split train test val (90-5-5)\n",
    "train, test = train_test_split(data, test_size=0.9, random_state=42, shuffle=True)\n",
    "val, test = train_test_split(test, test_size=0.5, random_state=42, shuffle=True)\n",
    "\n",
    "# use 10% of test to be around 5 min considering llama3.2:1b\n",
    "test = test.sample(frac=0.025, random_state=42)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(112, 2)"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Testing some techniques"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [],
   "source": [
    "_llm = OllamaLLM(model=\"llama3.2:1b\", temperature=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:sentence_transformers.SentenceTransformer:Use pytorch device_name: cuda\n",
      "INFO:sentence_transformers.SentenceTransformer:Load pretrained SentenceTransformer: sentence-transformers/all-MiniLM-L6-v2\n"
     ]
    }
   ],
   "source": [
    "loader = DataFrameLoader(train, page_content_column=\"question\")\n",
    "docs = loader.load()\n",
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=150, chunk_overlap=50)\n",
    "\n",
    "\n",
    "splits = text_splitter.split_documents(docs)\n",
    "\n",
    "embeddings_model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "embed = HuggingFaceEmbeddings(model_name=embeddings_model_name)\n",
    "\n",
    "vectorstore_questions = FAISS.from_documents(documents=splits, embedding=embed)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Multiquery"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('What is (are) Cataract ?', np.float32(0.83214307)),\n",
       " ('What are the symptoms of Cataract ?', np.float32(0.55580974)),\n",
       " ('What is (are) Macular degeneration ?', np.float32(0.30216485))]"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample = \"What is cataract?\"\n",
    "threshold = 0.1\n",
    "\n",
    "res = vectorstore_questions.similarity_search_with_relevance_scores(\n",
    "    sample,\n",
    "    k=3,\n",
    ")\n",
    "\n",
    "filtered_res = list(filter(lambda x: x[1] > threshold, res))\n",
    "\n",
    "[(doc[0].page_content, doc[1]) for doc in filtered_res]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['1. What causes cataracts in children?',\n",
       " '2. How are cataracts diagnosed?',\n",
       " '3. What are the symptoms of cataracts?']"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "prompt_multiquery = \"\"\"\n",
    "From provided question, return 3 new question trying to specify the context of the question. Separe them by newlines\n",
    "Answer only the new questions separeted by newlines, without any aditional information.\n",
    "Question:\n",
    "{query}\n",
    "\"\"\"\n",
    "\n",
    "queries = _llm.invoke(prompt_multiquery.format(query=sample)).split(\"\\n\")\n",
    "\n",
    "queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[(Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'), 0.5489493012428284), (Document(metadata={'answer': 'National Eye Institute National Institutes of Health 2020 Vision Place Bethesda, MD 20892-3655 301-496-5248 E-mail: 2020@nei.nih.gov www.nei.nih.gov For more information about intraocular lenses, or IOLs, contact: U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 1-888-463-6332 E-mail: webmail@oc.fda.gov'}, page_content='What is (are) Cataract ?'), 0.5271052718162537), (Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'), 0.3840634822845459)]\n",
      "[(Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'), 0.6517156362533569), (Document(metadata={'answer': 'National Eye Institute National Institutes of Health 2020 Vision Place Bethesda, MD 20892-3655 301-496-5248 E-mail: 2020@nei.nih.gov www.nei.nih.gov For more information about intraocular lenses, or IOLs, contact: U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 1-888-463-6332 E-mail: webmail@oc.fda.gov'}, page_content='What is (are) Cataract ?'), 0.6456401944160461), (Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'), 0.4852520823478699)]\n",
      "[(Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'), 0.9079616665840149), (Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'), 0.5752544403076172), (Document(metadata={'answer': 'What are the signs and symptoms of Cataracts, ataxia, short stature, and mental retardation? The Human Phenotype Ontology provides the following list of signs and symptoms for Cataracts, ataxia, short stature, and mental retardation. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Ataxia - Dysarthria - Intellectual disability - Muscle weakness - Muscular hypotonia - Posterior subcapsular cataract - Postural tremor - Short stature - X-linked recessive inheritance - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Cataracts, ataxia, short stature, and mental retardation ?'), 0.5626604557037354)]\n"
     ]
    }
   ],
   "source": [
    "results = []\n",
    "for query in queries:\n",
    "    res = vectorstore_questions.similarity_search_with_relevance_scores(\n",
    "        query,\n",
    "        k=3,\n",
    "    )\n",
    "\n",
    "    filtered_res = list(filter(lambda x: x[1] > threshold, res))\n",
    "    filtered_res = [(doc[0], doc[1].item()) for doc in filtered_res]\n",
    "\n",
    "    results.append(filtered_res)\n",
    "\n",
    "    print(filtered_res)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Rag-fusion test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.load import dumps, loads\n",
    "\n",
    "fused_scores = {}\n",
    "k = 60\n",
    "for docs in results:\n",
    "    for rank, doc in enumerate(docs):\n",
    "        doc_str = dumps(doc)\n",
    "        if doc_str not in fused_scores:\n",
    "            fused_scores[doc_str] = 0\n",
    "        previous_score = fused_scores[doc_str]\n",
    "        fused_scores[doc_str] += 1 / (rank + k)\n",
    "\n",
    "reranked_results = [\n",
    "    (loads(doc), score)\n",
    "    for doc, score in sorted(fused_scores.items(), key=lambda x: x[1], reverse=True)\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[([Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'),\n",
       "   0.5489493012428284],\n",
       "  0.016666666666666666),\n",
       " ([Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'),\n",
       "   0.6517156362533569],\n",
       "  0.016666666666666666),\n",
       " ([Document(metadata={'answer': 'The most common symptoms of a cataract are - cloudy or blurry vision - colors seem faded - glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights - poor night vision - double vision or multiple images in one eye - frequent prescription changes in your eyeglasses or contact lenses. cloudy or blurry vision colors seem faded glare -- headlights, lamps, or sunlight appearing too bright, or a halo may appear around lights poor night vision double vision or multiple images in one eye frequent prescription changes in your eyeglasses or contact lenses. These symptoms can also be a sign of other eye problems. If you have any of these symptoms, check with your eye care professional.'}, page_content='What are the symptoms of Cataract ?'),\n",
       "   0.9079616665840149],\n",
       "  0.016666666666666666),\n",
       " ([Document(metadata={'answer': 'National Eye Institute National Institutes of Health 2020 Vision Place Bethesda, MD 20892-3655 301-496-5248 E-mail: 2020@nei.nih.gov www.nei.nih.gov For more information about intraocular lenses, or IOLs, contact: U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 1-888-463-6332 E-mail: webmail@oc.fda.gov'}, page_content='What is (are) Cataract ?'),\n",
       "   0.5271052718162537],\n",
       "  0.01639344262295082),\n",
       " ([Document(metadata={'answer': 'National Eye Institute National Institutes of Health 2020 Vision Place Bethesda, MD 20892-3655 301-496-5248 E-mail: 2020@nei.nih.gov www.nei.nih.gov For more information about intraocular lenses, or IOLs, contact: U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 1-888-463-6332 E-mail: webmail@oc.fda.gov'}, page_content='What is (are) Cataract ?'),\n",
       "   0.6456401944160461],\n",
       "  0.01639344262295082),\n",
       " ([Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'),\n",
       "   0.5752544403076172],\n",
       "  0.01639344262295082),\n",
       " ([Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'),\n",
       "   0.3840634822845459],\n",
       "  0.016129032258064516),\n",
       " ([Document(metadata={'answer': 'What are the signs and symptoms of Autosomal dominant optic atrophy and cataract? The Human Phenotype Ontology provides the following list of signs and symptoms for Autosomal dominant optic atrophy and cataract. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Abnormality of extrapyramidal motor function - Autosomal dominant inheritance - Cataract - Optic atrophy - Reduced visual acuity - Tremor - Visual impairment - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Autosomal dominant optic atrophy and cataract ?'),\n",
       "   0.4852520823478699],\n",
       "  0.016129032258064516),\n",
       " ([Document(metadata={'answer': 'What are the signs and symptoms of Cataracts, ataxia, short stature, and mental retardation? The Human Phenotype Ontology provides the following list of signs and symptoms for Cataracts, ataxia, short stature, and mental retardation. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Ataxia - Dysarthria - Intellectual disability - Muscle weakness - Muscular hypotonia - Posterior subcapsular cataract - Postural tremor - Short stature - X-linked recessive inheritance - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='What are the symptoms of Cataracts, ataxia, short stature, and mental retardation ?'),\n",
       "   0.5626604557037354],\n",
       "  0.016129032258064516)]"
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "reranked_results"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Different flows to question x answer x non-context (HyDE like generation)\n",
    "\n",
    "Let's make some discussoes about the flows:\n",
    "\n",
    "If we match directly the question with high similarity score, that's the best case. Only need to give the retrieved docs to the model (maybe look to context size).\n",
    "\n",
    "As a feature of the dataset, we have more information in the answers than in the questions. The user question can be mo involved in part of the answer. In case when we don't match any question, I'll try to match some chunk of answer.\n",
    "\n",
    "If no one match occurs, we rely in open generation. That point can be covered by guardrails or maybe be a point of \"No answer\" to the user."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6490</th>\n",
       "      <td>What are the treatments for Progressive transf...</td>\n",
       "      <td>What treatment is available for progressive tr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8609</th>\n",
       "      <td>How to diagnose Heart Palpitations ?</td>\n",
       "      <td>First, your doctor will want to find out wheth...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9978</th>\n",
       "      <td>What are the genetic changes related to mucopo...</td>\n",
       "      <td>Mutations in the ARSB gene cause MPS VI. The A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8070</th>\n",
       "      <td>How to diagnose Parasites - Schistosomiasis ?</td>\n",
       "      <td>Stool or urine samples can be examined microsc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8577</th>\n",
       "      <td>Who is at risk for Iron-Deficiency Anemia? ?</td>\n",
       "      <td>Infants and Young Children Infants and young c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5734</th>\n",
       "      <td>What causes Relapsing polychondritis ?</td>\n",
       "      <td>What causes relapsing polychondritis? The exac...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5191</th>\n",
       "      <td>What is (are) Leprechaunism ?</td>\n",
       "      <td>Leprechaunism is a congenital (present from bi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5390</th>\n",
       "      <td>What are the treatments for Hallermann-Streiff...</td>\n",
       "      <td>How might Hallermann-Streiff syndrome be treat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>860</th>\n",
       "      <td>What are the stages of Uterine Sarcoma ?</td>\n",
       "      <td>Key Points - After uterine sarcoma has been di...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7270</th>\n",
       "      <td>What are the treatments for Thalassemia ?</td>\n",
       "      <td>How might thalassemia be treated? The best tre...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1000 rows Ã— 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               question  \\\n",
       "6490  What are the treatments for Progressive transf...   \n",
       "8609               How to diagnose Heart Palpitations ?   \n",
       "9978  What are the genetic changes related to mucopo...   \n",
       "8070      How to diagnose Parasites - Schistosomiasis ?   \n",
       "8577       Who is at risk for Iron-Deficiency Anemia? ?   \n",
       "...                                                 ...   \n",
       "5734             What causes Relapsing polychondritis ?   \n",
       "5191                      What is (are) Leprechaunism ?   \n",
       "5390  What are the treatments for Hallermann-Streiff...   \n",
       "860            What are the stages of Uterine Sarcoma ?   \n",
       "7270          What are the treatments for Thalassemia ?   \n",
       "\n",
       "                                                 answer  \n",
       "6490  What treatment is available for progressive tr...  \n",
       "8609  First, your doctor will want to find out wheth...  \n",
       "9978  Mutations in the ARSB gene cause MPS VI. The A...  \n",
       "8070  Stool or urine samples can be examined microsc...  \n",
       "8577  Infants and Young Children Infants and young c...  \n",
       "...                                                 ...  \n",
       "5734  What causes relapsing polychondritis? The exac...  \n",
       "5191  Leprechaunism is a congenital (present from bi...  \n",
       "5390  How might Hallermann-Streiff syndrome be treat...  \n",
       "860   Key Points - After uterine sarcoma has been di...  \n",
       "7270  How might thalassemia be treated? The best tre...  \n",
       "\n",
       "[1000 rows x 2 columns]"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [],
   "source": [
    "train[\"complete_answer\"] = train[\"answer\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "loader = DataFrameLoader(train, page_content_column=\"answer\")\n",
    "docs = loader.load()\n",
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=128, chunk_overlap=64)\n",
    "\n",
    "\n",
    "splits = text_splitter.split_documents(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'question': 'What are the treatments for Childhood Central Nervous System Embryonal Tumors ?', 'complete_answer': \"Key Points - There are different types of treatment for children who have central nervous system (CNS) embryonal tumors. - Children who have CNS embryonal tumors should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children. - Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years. - Some cancer treatments cause side effects months or years after treatment has ended. - Five types of treatment are used: - Surgery - Radiation therapy - Chemotherapy - High-dose chemotherapy with stem cell rescue - Targeted therapy - New types of treatment are being tested in clinical trials. - Patients may want to think about taking part in a clinical trial. - Patients can enter clinical trials before, during, or after starting their cancer treatment. - Follow-up tests may be needed. There are different types of treatment for children who have central nervous system (CNS) embryonal tumors. Different types of treatment are available for children with central nervous system (CNS) embryonal tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment. Children who have CNS embryonal tumors should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children. Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. These may include the following specialists: - Pediatrician. - Neurosurgeon. - Neurologist. - Neuropathologist. - Neuroradiologist. - Rehabilitation specialist. - Radiation oncologist. - Psychologist. Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years. Signs or symptoms caused by the tumor may begin before the cancer is diagnosed and continue for months or years. It is important to talk with your child's doctors about signs or symptoms caused by the tumor that may continue after treatment. Some cancer treatments cause side effects months or years after treatment has ended. Side effects from cancer treatment that begin during or after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following: - Physical problems. - Changes in mood, feelings, thinking, learning, or memory. - Second cancers (new types of cancer). Children diagnosed with medulloblastoma may have certain problems after surgery or radiation therapy such as changes in the ability to think, learn, and pay attention. Also, cerebellar mutism syndrome may occur after surgery. Signs of this syndrome include the following: - Delayed ability to speak. - Trouble swallowing and eating. - Loss of balance, trouble walking, and worsening handwriting. - Loss of muscle tone. - Mood swings and changes in personality. Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information). Five types of treatment are used: Surgery Surgery is used to diagnose and treat a childhood CNS embryonal tumor as described in the General Information section of this summary. Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy and/or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy. Radiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy: - External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following: - Conformal radiation therapy: Conformal radiation therapy is a type of external radiation therapy that uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor. This allows a high dose of radiation to reach the tumor and causes less damage to nearby healthy tissue. - Stereotactic radiation therapy: Stereotactic radiation therapy is a type of external radiation therapy. A rigid head frame is attached to the skull to keep the head still during the radiation treatment. A machine aims radiation directly at the tumor, causing less damage to nearby healthy tissue. The total dose of radiation is divided into several smaller doses given over several days. This procedure is also called stereotactic external-beam radiation therapy and stereotaxic radiation therapy. - Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Radiation therapy to the brain can affect growth and development in young children. For this reason, clinical trials are studying new ways of giving radiation that may have fewer side effects than standard methods. The way the radiation therapy is given depends on the type of cancer being treated. External radiation therapy is used to treat childhood CNS embryonal tumors. Because radiation therapy can affect growth and brain development in young children, especially children who are three years old or younger, chemotherapy may be given to delay or reduce the need for radiation therapy. Chemotherapy Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug. The way the chemotherapy is given depends on the type of cancer being treated. Regular dose anticancer drugs given by mouth or vein to treat central nervous system tumors cannot cross the blood-brain barrier and enter the fluid that surrounds the brain and spinal cord. Instead, an anticancer drug is injected into the fluid-filled space to kill cancer cells that may have spread there. This is called intrathecal or intraventricular chemotherapy. High-dose chemotherapy with stem cell rescue High-dose chemotherapy with stem cell rescue is a way of giving high doses of chemotherapy and replacing blood -forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the bodys blood cells. Targeted therapy Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Signal transduction inhibitors are a type of targeted therapy used to treat recurrent medulloblastoma. Signal transduction inhibitors block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. Vismodegib is a type of signal transduction inhibitor. New types of treatment are being tested in clinical trials. Information about clinical trials is available from the NCI website. Patients may want to think about taking part in a clinical trial. For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment. Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment. Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward. Patients can enter clinical trials before, during, or after starting their cancer treatment. Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment. Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials. Follow-up tests may be needed. Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. (See the General Information section for a list of tests.) Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests. This is sometimes called re-staging. Some of the imaging tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the brain tumor has recurred (come back). If the imaging tests show abnormal tissue in the brain, a biopsy may also be done to find out if the tissue is made up of dead tumor cells or if new cancer cells are growing. These tests are sometimes called follow-up tests or check-ups. Treatment Options for Childhood Central Nervous System Embryonal Tumors and Childhood Pineoblastoma Newly Diagnosed Childhood Medulloblastoma In newly diagnosed childhood medulloblastoma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve signs or symptoms caused by the tumor. Children older than 3 years with average-risk medulloblastoma Standard treatment of average-risk medulloblastoma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. Children older than 3 years with high-risk medulloblastoma Standard treatment of high-risk medulloblastoma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by a larger dose of radiation therapy to the brain and spinal cord than the dose given for average-risk medulloblastoma. Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. - A clinical trial of new combinations of radiation therapy and chemotherapy. Children aged 3 years and younger Standard treatment of medulloblastoma in children aged 3 years and younger is: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. Other treatments that may be given after surgery include the following: - Chemotherapy with or without radiation therapy to the area where the tumor was removed. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood medulloblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Nonmedulloblastoma Embryonal Tumors In newly diagnosed childhood nonmedulloblastoma embryonal tumors, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of nonmedulloblastoma embryonal tumors in children older than 3 years is: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy is also given during and after radiation therapy. Children aged 3 years and younger Standard treatment of nonmedulloblastoma embryonal tumors in children aged 3 years and younger is: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. Other treatments that may be given after surgery include the following: - Chemotherapy and radiation therapy to the area where the tumor was removed. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood nonmedulloblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Medulloepithelioma In newly diagnosed childhood medulloepithelioma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of medulloepithelioma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. - A clinical trial of new combinations of radiation therapy and chemotherapy. Children aged 3 years and younger Standard treatment of medulloepithelioma in children aged 3 years and younger includes the following: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. - High-dose chemotherapy with stem cell rescue. - Radiation therapy, when the child is older. - A clinical trial of new combinations and schedules of chemotherapy or new combinations of chemotherapy with stem cell rescue. Treatment of medulloepithelioma in children aged 3 years and younger is often within a clinical trial. Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood medulloepithelioma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Pineoblastoma In newly diagnosed childhood pineoblastoma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of pineoblastoma in children older than 3 years includes the following: - Surgery to remove the tumor. The tumor usually cannot be completely removed because of where it is in the brain. Surgery is often followed by radiation therapy to the brain and spinal cord and chemotherapy. - A clinical trial of high-dose chemotherapy after radiation therapy and stem cell rescue. - A clinical trial of chemotherapy during radiation therapy. Children aged 3 years and younger Standard treatment of pineoblastoma in children aged 3 years and younger includes the following: - Biopsy to diagnose pineoblastoma followed by chemotherapy. - If the tumor responds to chemotherapy, radiation therapy is given when the child is older. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood pineoblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Recurrent Childhood Central Nervous System Embryonal Tumors and Pineoblastomas The treatment of central nervous system (CNS) embryonal tumors and pineoblastoma that recur (come back) depends on: - The type of tumor. - Whether the tumor recurred where it first formed or has spread to other parts of the brain, spinal cord, or body. - The type of treatment given in the past. - How much time has passed since the initial treatment ended. - Whether the patient has signs or symptoms. Treatment for recurrent childhood CNS embryonal tumors and pineoblastomas may include the following: - For children who previously received radiation therapy and chemotherapy, treatment may include repeat radiation at the site where the cancer started and where the tumor has spread. Stereotactic radiation therapy and/or chemotherapy may also be used. - For infants and young children who previously received chemotherapy only and have a local recurrence, treatment may be chemotherapy with radiation therapy to the tumor and the area close to it. Surgery to remove the tumor may also be done. - For patients who previously received radiation therapy, high-dose chemotherapy and stem cell rescue may be used. It is not known whether this treatment improves survival. - Targeted therapy with a signal transduction inhibitor for patients whose cancer has certain changes in the genes. Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent childhood central nervous system embryonal tumor. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\"}, page_content='radiation therapy. Children aged 3 years and younger Standard treatment of pineoblastoma in children aged 3 years and younger'),\n",
       " Document(metadata={'question': 'What are the symptoms of Fanconi Anemia ?', 'complete_answer': \"Major Signs and Symptoms Your doctor may suspect you or your child has Fanconi anemia (FA) if you have signs and symptoms of: Anemia Bone marrow failure Birth defects Developmental or eating problems FA is an inherited disorderthat is, it's passed from parents to children through genes. If a child has FA, his or her brothers and sisters also should be tested for the disorder. Anemia The most common symptom of all types of anemia is fatigue (tiredness). Fatigue occurs because your body doesn't have enough red blood cells to carry oxygen to its various parts. If you have anemia, you may not have the energy to do normal activities. A low red blood cell count also can cause shortness of breath, dizziness, headaches, coldness in your hands and feet, pale skin, and chest pain. Bone Marrow Failure When your bone marrow fails, it can't make enough red blood cells, white blood cells, and platelets. This can cause many problems that have various signs and symptoms. With too few red blood cells, you can develop anemia. In FA, the size of your red blood cells also can be much larger than normal. This makes it harder for the cells to work well. With too few white blood cells, you're at risk for infections. Infections also may last longer and be more serious than normal. With too few platelets, you may bleed and bruise easily, suffer from internal bleeding, or have petechiae (pe-TEE-kee-ay). Petechiae are tiny red or purple spots on the skin. Bleeding in small blood vessels just below your skin causes these spots. In some people who have FA, the bone marrow makes a lot of harmful, immature white blood cells called blasts. Blasts don't work like normal blood cells. As they build up, they prevent the bone marrow from making enough normal blood cells. A large number of blasts in the bone marrow can lead to a type of blood cancer called acute myeloid leukemia (AML). Birth Defects Many birth defects can be signs of FA. These include: Bone or skeletal defects. FA can cause missing, oddly shaped, or three or more thumbs. Arm bones, hips, legs, hands, and toes may not form fully or normally. People who have FA may have a curved spine, a condition called scoliosis (sco-le-O-sis). Eye and ear defects. The eyes, eyelids, and ears may not have a normal shape. Children who have FA also might be born deaf. Skin discoloration. This includes coffee-colored areas or odd-looking patches of lighter skin. Kidney problems. A child who has FA might be born with a missing kidney or kidneys that aren't shaped normally. Congenital heart defects. The most common congenital heart defect linked to FA is a ventricular septal defect (VSD). A VSD is a hole or defect in the lower part of the wall that separates the hearts left and right chambers. Developmental Problems Other signs and symptoms of FA are related to physical and mental development. They include: Low birth weight Poor appetite Delayed growth Below-average height Small head size Mental retardation or learning disabilities Signs and Symptoms of Fanconi Anemia in Adults Some signs and symptoms of FA may develop as you or your child gets older. Women who have FA may have some or all of the following: Sex organs that are less developed than normal Menstruating later than women who don't have FA Starting menopause earlier than women who don't have FA Problems getting pregnant and carrying a pregnancy to full term Men who have FA may have sex organs that are less developed than normal. They also may be less fertile than men who don't have the disease.\"}, page_content=\"normal. They also may be less fertile than men who don't have the disease.\"),\n",
       " Document(metadata={'question': 'What are the symptoms of Familial juvenile hyperuricaemic nephropathy ?', 'complete_answer': 'What are the signs and symptoms of Familial juvenile hyperuricaemic nephropathy? The Human Phenotype Ontology provides the following list of signs and symptoms for Familial juvenile hyperuricaemic nephropathy. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Autosomal dominant inheritance - Gout - Juvenile onset - Nephropathy - Progressive - Renal insufficiency - Tubular atrophy - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.'}, page_content='25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions')]"
      ]
     },
     "execution_count": 112,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "random.seed(42)\n",
    "random.sample(splits, 3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:sentence_transformers.SentenceTransformer:Use pytorch device_name: cuda\n",
      "INFO:sentence_transformers.SentenceTransformer:Load pretrained SentenceTransformer: sentence-transformers/all-MiniLM-L6-v2\n"
     ]
    }
   ],
   "source": [
    "embeddings_model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "embed = HuggingFaceEmbeddings(model_name=embeddings_model_name)\n",
    "\n",
    "vectorstore_answers = FAISS.from_documents(documents=splits, embedding=embed)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieve from questions:\n",
      "Is Castleman disease inherited ? 0.30561018\n",
      "What is (are) Waardenburg syndrome type 2 ? 0.30231\n",
      "Is Danon disease inherited ? 0.29219258\n",
      "\n",
      "Retrieve from answers:\n",
      "What is (are) Septo-optic dysplasia ?\n",
      "(HESX1, OTX2, and SOX2) have been associated with septo-optic dysplasia. Typically, people do not ha 0.51054955\n",
      "\n",
      "Who is at risk for Prostate Cancer? ?\n",
      "of families who have several members with the disease. Other studies are trying to identify which ge 0.4813087\n",
      "\n",
      "What is (are) Familial prostate cancer ?\n",
      "HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other sha 0.44659787\n",
      "\n"
     ]
    }
   ],
   "source": [
    "sample = \"three genes (HESX1, OTX2, and SOX2) have been associated to some disease?\"\n",
    "\n",
    "print(\"Retrieve from questions:\")\n",
    "res = vectorstore_questions.similarity_search_with_relevance_scores(sample, k=3)\n",
    "for i in res:\n",
    "    print(i[0].page_content, i[1])\n",
    "print()\n",
    "print(\"Retrieve from answers:\")\n",
    "res = vectorstore_answers.similarity_search_with_relevance_scores(sample, k=3)\n",
    "for i in res:\n",
    "    print(i[0].metadata[\"question\"])\n",
    "    print(i[0].page_content[:100], i[1])\n",
    "    print()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Retrieval summarization\n",
    "\n",
    "Some answer can have more than 5k of tokens. We can use some summarization technique to reduce the size of the answer.\n",
    "\n",
    "In the real life scenario it's interestig to pre-compute and add to our dataset. In my rushed scenario about the deadline, I'll put that on the inferece."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [],
   "source": [
    "import tiktoken\n",
    "\n",
    "tokenizer = tiktoken.get_encoding(\"o200k_base\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [],
   "source": [
    "train[\"answer_tokens\"] = train[\"answer\"].apply(lambda i: len(tokenizer.encode(i)))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 151,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Axes: ylabel='Frequency'>"
      ]
     },
     "execution_count": 151,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "train[\"answer_tokens\"].plot.hist(bins=100, alpha=0.5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>complete_answer</th>\n",
       "      <th>answer_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1267</th>\n",
       "      <td>What are the treatments for Childhood Central ...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>3704</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1167</th>\n",
       "      <td>What are the treatments for Prostate Cancer ?</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>3560</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1484</th>\n",
       "      <td>What are the treatments for Langerhans Cell Hi...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>3474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>853</th>\n",
       "      <td>What are the treatments for Childhood Extracra...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>3104</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1081</th>\n",
       "      <td>What are the treatments for Bile Duct Cancer (...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>Key Points - There are different types of trea...</td>\n",
       "      <td>2831</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               question  \\\n",
       "1267  What are the treatments for Childhood Central ...   \n",
       "1167      What are the treatments for Prostate Cancer ?   \n",
       "1484  What are the treatments for Langerhans Cell Hi...   \n",
       "853   What are the treatments for Childhood Extracra...   \n",
       "1081  What are the treatments for Bile Duct Cancer (...   \n",
       "\n",
       "                                                 answer  \\\n",
       "1267  Key Points - There are different types of trea...   \n",
       "1167  Key Points - There are different types of trea...   \n",
       "1484  Key Points - There are different types of trea...   \n",
       "853   Key Points - There are different types of trea...   \n",
       "1081  Key Points - There are different types of trea...   \n",
       "\n",
       "                                        complete_answer  answer_tokens  \n",
       "1267  Key Points - There are different types of trea...           3704  \n",
       "1167  Key Points - There are different types of trea...           3560  \n",
       "1484  Key Points - There are different types of trea...           3474  \n",
       "853   Key Points - There are different types of trea...           3104  \n",
       "1081  Key Points - There are different types of trea...           2831  "
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.sort_values(\"answer_tokens\", ascending=False).head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [],
   "source": [
    "long_sample = train.sort_values(\"answer_tokens\", ascending=False).iloc[0][\"answer\"]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Take around 30s to summarize one sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt = \"\"\"\n",
    "Summarize the following text in 100 words. Answer only the summarization, without any aditional information.\n",
    "\n",
    "Text:\n",
    "{sample}\n",
    "\"\"\"\n",
    "\n",
    "summary = _llm.invoke(prompt.format(sample=long_sample))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"The text appears to be a summary of cancer treatment options and clinical trials for children with medulloepithelioma, pineoblastoma, and recurrent CNS embryonal tumors and pineoblastomas. Here are some key points:\\n\\n**Medulloepithelioma:**\\n\\n* The tumor itself has not been treated.\\n* Treatment may include surgery to remove as much of the tumor as possible, followed by radiation therapy to the brain and spinal cord, and chemotherapy.\\n* Clinical trials for new combinations of radiation therapy and chemotherapy are being explored.\\n\\n**Pineoblastoma:**\\n\\n* The tumor itself has not been treated.\\n* Treatment may include surgery to remove the tumor, followed by radiation therapy to the brain and spinal cord, and chemotherapy.\\n* Clinical trials for high-dose chemotherapy after radiation therapy and stem cell rescue, as well as chemotherapy during radiation therapy, are being explored.\\n\\n**Recurrent CNS Embryonal Tumors and Pineoblastomas:**\\n\\n* Treatment depends on the type of tumor, whether it has recurred where it first formed or spread to other parts of the brain, spinal cord, or body.\\n* Treatment may include repeat radiation at the site where the cancer started and where the tumor has spread, as well as chemotherapy with radiation therapy.\\n* Surgery to remove the tumor may also be done.\\n\\n**General Information:**\\n\\n* Clinical trials for childhood medulloepithelioma, pineoblastoma, and recurrent CNS embryonal tumors and pineoblastomas are now accepting patients.\\n* General information about clinical trials is available from the NCI website.\\n* Patients should talk with their child's doctor about clinical trials that may be right for their child.\\n\\n**Key Takeaways:**\\n\\n* Children with medulloepithelioma, pineoblastoma, and recurrent CNS embryonal tumors and pineoblastomas should discuss treatment options with their doctor.\\n* Clinical trials are available to explore new treatments and improve outcomes.\\n* Patients should talk with their doctor about clinical trials that may be right for their child.\""
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "summary"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's take other way, chunk -> extented_chunk match.\n",
    "\n",
    "About the positional information bias, we can consider if we match some part of a chunk, use around information (consider overlap) can be better than only use open generation."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [],
   "source": [
    "_train = train.copy()\n",
    "\n",
    "new_train = pd.DataFrame(\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "loader = DataFrameLoader(train, page_content_column=\"complete_answer\")\n",
    "docs = loader.load()\n",
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=128, chunk_overlap=64)\n",
    "\n",
    "\n",
    "splits = text_splitter.split_documents(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "question           What are the treatments for Progressive transf...\n",
       "answer             What treatment is available for progressive tr...\n",
       "complete_answer    What treatment is available for progressive tr...\n",
       "answer_tokens                                                     96\n",
       "Name: 6490, dtype: object"
      ]
     },
     "execution_count": 137,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "_train.iloc[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Testing semantic chunking, but still like 2.5s/sample.\n",
    "For now, I think that's ok because the number of sample with more than 5k tokens is low. Let's keep all"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(123, 4)"
      ]
     },
     "execution_count": 150,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train[train[\"answer_tokens\"] > 512].shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:sentence_transformers.SentenceTransformer:Use pytorch device_name: cuda\n",
      "INFO:sentence_transformers.SentenceTransformer:Load pretrained SentenceTransformer: sentence-transformers/all-MiniLM-L6-v2\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Key Points - There are different types of treatment for children who have central nervous system (CNS) embryonal tumors. - Children who have CNS embryonal tumors should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children. - Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years. - Some cancer treatments cause side effects months or years after treatment has ended. - Five types of treatment are used: - Surgery - Radiation therapy - Chemotherapy - High-dose chemotherapy with stem cell rescue - Targeted therapy - New types of treatment are being tested in clinical trials. - Patients may want to think about taking part in a clinical trial. - Patients can enter clinical trials before, during, or after starting their cancer treatment. - Follow-up tests may be needed. There are different types of treatment for children who have central nervous system (CNS) embryonal tumors. Different types of treatment are available for children with central nervous system (CNS) embryonal tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment. Children who have CNS embryonal tumors should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children. Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. These may include the following specialists: - Pediatrician. - Neurosurgeon. - Neurologist. - Neuropathologist. - Neuroradiologist. - Rehabilitation specialist. - Radiation oncologist.', \"- Psychologist. Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years. Signs or symptoms caused by the tumor may begin before the cancer is diagnosed and continue for months or years. It is important to talk with your child's doctors about signs or symptoms caused by the tumor that may continue after treatment. Some cancer treatments cause side effects months or years after treatment has ended. Side effects from cancer treatment that begin during or after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following: - Physical problems. - Changes in mood, feelings, thinking, learning, or memory.\", '- Second cancers (new types of cancer). Children diagnosed with medulloblastoma may have certain problems after surgery or radiation therapy such as changes in the ability to think, learn, and pay attention. Also, cerebellar mutism syndrome may occur after surgery. Signs of this syndrome include the following: - Delayed ability to speak. - Trouble swallowing and eating. - Loss of balance, trouble walking, and worsening handwriting. - Loss of muscle tone. - Mood swings and changes in personality.', \"Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information). Five types of treatment are used: Surgery Surgery is used to diagnose and treat a childhood CNS embryonal tumor as described in the General Information section of this summary. Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy and/or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy. Radiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy: - External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following: - Conformal radiation therapy: Conformal radiation therapy is a type of external radiation therapy that uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor. This allows a high dose of radiation to reach the tumor and causes less damage to nearby healthy tissue. - Stereotactic radiation therapy: Stereotactic radiation therapy is a type of external radiation therapy. A rigid head frame is attached to the skull to keep the head still during the radiation treatment. A machine aims radiation directly at the tumor, causing less damage to nearby healthy tissue. The total dose of radiation is divided into several smaller doses given over several days. This procedure is also called stereotactic external-beam radiation therapy and stereotaxic radiation therapy. - Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Radiation therapy to the brain can affect growth and development in young children. For this reason, clinical trials are studying new ways of giving radiation that may have fewer side effects than standard methods. The way the radiation therapy is given depends on the type of cancer being treated. External radiation therapy is used to treat childhood CNS embryonal tumors. Because radiation therapy can affect growth and brain development in young children, especially children who are three years old or younger, chemotherapy may be given to delay or reduce the need for radiation therapy. Chemotherapy Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug. The way the chemotherapy is given depends on the type of cancer being treated. Regular dose anticancer drugs given by mouth or vein to treat central nervous system tumors cannot cross the blood-brain barrier and enter the fluid that surrounds the brain and spinal cord. Instead, an anticancer drug is injected into the fluid-filled space to kill cancer cells that may have spread there. This is called intrathecal or intraventricular chemotherapy. High-dose chemotherapy with stem cell rescue High-dose chemotherapy with stem cell rescue is a way of giving high doses of chemotherapy and replacing blood -forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the bodys blood cells. Targeted therapy Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Signal transduction inhibitors are a type of targeted therapy used to treat recurrent medulloblastoma. Signal transduction inhibitors block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. Vismodegib is a type of signal transduction inhibitor. New types of treatment are being tested in clinical trials.\", \"Information about clinical trials is available from the NCI website. Patients may want to think about taking part in a clinical trial. For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment. Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment. Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward. Patients can enter clinical trials before, during, or after starting their cancer treatment. Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment. Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials. Follow-up tests may be needed. Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. (See the General Information section for a list of tests.) Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests. This is sometimes called re-staging. Some of the imaging tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the brain tumor has recurred (come back). If the imaging tests show abnormal tissue in the brain, a biopsy may also be done to find out if the tissue is made up of dead tumor cells or if new cancer cells are growing. These tests are sometimes called follow-up tests or check-ups. Treatment Options for Childhood Central Nervous System Embryonal Tumors and Childhood Pineoblastoma Newly Diagnosed Childhood Medulloblastoma In newly diagnosed childhood medulloblastoma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve signs or symptoms caused by the tumor. Children older than 3 years with average-risk medulloblastoma Standard treatment of average-risk medulloblastoma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord.\", \"Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. Children older than 3 years with high-risk medulloblastoma Standard treatment of high-risk medulloblastoma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by a larger dose of radiation therapy to the brain and spinal cord than the dose given for average-risk medulloblastoma. Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. - A clinical trial of new combinations of radiation therapy and chemotherapy. Children aged 3 years and younger Standard treatment of medulloblastoma in children aged 3 years and younger is: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. Other treatments that may be given after surgery include the following: - Chemotherapy with or without radiation therapy to the area where the tumor was removed. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood medulloblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Nonmedulloblastoma Embryonal Tumors In newly diagnosed childhood nonmedulloblastoma embryonal tumors, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of nonmedulloblastoma embryonal tumors in children older than 3 years is: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy is also given during and after radiation therapy. Children aged 3 years and younger Standard treatment of nonmedulloblastoma embryonal tumors in children aged 3 years and younger is: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. Other treatments that may be given after surgery include the following: - Chemotherapy and radiation therapy to the area where the tumor was removed. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood nonmedulloblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Medulloepithelioma In newly diagnosed childhood medulloepithelioma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of medulloepithelioma in children older than 3 years includes the following: - Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord.\", 'Chemotherapy is also given during and after radiation therapy. - Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue. - A clinical trial of new combinations of radiation therapy and chemotherapy. Children aged 3 years and younger Standard treatment of medulloepithelioma in children aged 3 years and younger includes the following: - Surgery to remove as much of the tumor as possible, followed by chemotherapy. - High-dose chemotherapy with stem cell rescue.', \"- Radiation therapy, when the child is older. - A clinical trial of new combinations and schedules of chemotherapy or new combinations of chemotherapy with stem cell rescue. Treatment of medulloepithelioma in children aged 3 years and younger is often within a clinical trial. Check the list of NCI-supported cancer clinical trials that are now accepting patients with childhood medulloepithelioma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Newly Diagnosed Childhood Pineoblastoma In newly diagnosed childhood pineoblastoma, the tumor itself has not been treated. The child may have received drugs or treatment to relieve symptoms caused by the tumor. Children older than 3 years Standard treatment of pineoblastoma in children older than 3 years includes the following: - Surgery to remove the tumor. The tumor usually cannot be completely removed because of where it is in the brain.\", \"Surgery is often followed by radiation therapy to the brain and spinal cord and chemotherapy. - A clinical trial of high-dose chemotherapy after radiation therapy and stem cell rescue. - A clinical trial of chemotherapy during radiation therapy. Children aged 3 years and younger Standard treatment of pineoblastoma in children aged 3 years and younger includes the following: - Biopsy to diagnose pineoblastoma followed by chemotherapy. - If the tumor responds to chemotherapy, radiation therapy is given when the child is older. - High-dose chemotherapy with stem cell rescue. Check the list of NCI-supported cancer clinical trials that are now accepting patients with untreated childhood pineoblastoma. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website. Recurrent Childhood Central Nervous System Embryonal Tumors and Pineoblastomas The treatment of central nervous system (CNS) embryonal tumors and pineoblastoma that recur (come back) depends on: - The type of tumor. - Whether the tumor recurred where it first formed or has spread to other parts of the brain, spinal cord, or body.\", '- The type of treatment given in the past. - How much time has passed since the initial treatment ended.', \"- Whether the patient has signs or symptoms. Treatment for recurrent childhood CNS embryonal tumors and pineoblastomas may include the following: - For children who previously received radiation therapy and chemotherapy, treatment may include repeat radiation at the site where the cancer started and where the tumor has spread. Stereotactic radiation therapy and/or chemotherapy may also be used. - For infants and young children who previously received chemotherapy only and have a local recurrence, treatment may be chemotherapy with radiation therapy to the tumor and the area close to it. Surgery to remove the tumor may also be done. - For patients who previously received radiation therapy, high-dose chemotherapy and stem cell rescue may be used. It is not known whether this treatment improves survival. - Targeted therapy with a signal transduction inhibitor for patients whose cancer has certain changes in the genes. Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent childhood central nervous system embryonal tumor. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\"]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[431, 134, 100, 926, 565, 686, 96, 226, 266, 22, 253]"
      ]
     },
     "execution_count": 145,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain_experimental.text_splitter import SemanticChunker\n",
    "\n",
    "embeddings_model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "embed = HuggingFaceEmbeddings(model_name=embeddings_model_name)\n",
    "\n",
    "\n",
    "def chunk_answers(answer):\n",
    "    text_splitter = SemanticChunker(embed, breakpoint_threshold_type=\"percentile\")\n",
    "    # text_splitter = RecursiveCharacterTextSplitter(chunk_size=256, chunk_overlap=64)\n",
    "    return [i.page_content for i in text_splitter.create_documents([answer])]\n",
    "\n",
    "\n",
    "long_sample_chunked = chunk_answers(long_sample)\n",
    "\n",
    "print(long_sample_chunked)\n",
    "\n",
    "list(map(lambda i: len(tokenizer.encode(i)), long_sample_chunked))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [],
   "source": [
    "train[\"answer_chunks\"] = train[\"answer\"].apply(chunk_answers)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>complete_answer</th>\n",
       "      <th>answer_tokens</th>\n",
       "      <th>answer_chunks</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6490</th>\n",
       "      <td>What are the treatments for Progressive transf...</td>\n",
       "      <td>What treatment is available for progressive tr...</td>\n",
       "      <td>What treatment is available for progressive tr...</td>\n",
       "      <td>96</td>\n",
       "      <td>[What treatment is available for progressive t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8609</th>\n",
       "      <td>How to diagnose Heart Palpitations ?</td>\n",
       "      <td>First, your doctor will want to find out wheth...</td>\n",
       "      <td>First, your doctor will want to find out wheth...</td>\n",
       "      <td>873</td>\n",
       "      <td>[First, your doctor will want to find out whet...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9978</th>\n",
       "      <td>What are the genetic changes related to mucopo...</td>\n",
       "      <td>Mutations in the ARSB gene cause MPS VI. The A...</td>\n",
       "      <td>Mutations in the ARSB gene cause MPS VI. The A...</td>\n",
       "      <td>220</td>\n",
       "      <td>[Mutations in the ARSB gene cause MPS VI. The ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8070</th>\n",
       "      <td>How to diagnose Parasites - Schistosomiasis ?</td>\n",
       "      <td>Stool or urine samples can be examined microsc...</td>\n",
       "      <td>Stool or urine samples can be examined microsc...</td>\n",
       "      <td>81</td>\n",
       "      <td>[Stool or urine samples can be examined micros...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8577</th>\n",
       "      <td>Who is at risk for Iron-Deficiency Anemia? ?</td>\n",
       "      <td>Infants and Young Children Infants and young c...</td>\n",
       "      <td>Infants and Young Children Infants and young c...</td>\n",
       "      <td>674</td>\n",
       "      <td>[Infants and Young Children Infants and young ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5734</th>\n",
       "      <td>What causes Relapsing polychondritis ?</td>\n",
       "      <td>What causes relapsing polychondritis? The exac...</td>\n",
       "      <td>What causes relapsing polychondritis? The exac...</td>\n",
       "      <td>211</td>\n",
       "      <td>[What causes relapsing polychondritis? The exa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5191</th>\n",
       "      <td>What is (are) Leprechaunism ?</td>\n",
       "      <td>Leprechaunism is a congenital (present from bi...</td>\n",
       "      <td>Leprechaunism is a congenital (present from bi...</td>\n",
       "      <td>85</td>\n",
       "      <td>[Leprechaunism is a congenital (present from b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5390</th>\n",
       "      <td>What are the treatments for Hallermann-Streiff...</td>\n",
       "      <td>How might Hallermann-Streiff syndrome be treat...</td>\n",
       "      <td>How might Hallermann-Streiff syndrome be treat...</td>\n",
       "      <td>270</td>\n",
       "      <td>[How might Hallermann-Streiff syndrome be trea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>860</th>\n",
       "      <td>What are the stages of Uterine Sarcoma ?</td>\n",
       "      <td>Key Points - After uterine sarcoma has been di...</td>\n",
       "      <td>Key Points - After uterine sarcoma has been di...</td>\n",
       "      <td>1537</td>\n",
       "      <td>[Key Points - After uterine sarcoma has been d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7270</th>\n",
       "      <td>What are the treatments for Thalassemia ?</td>\n",
       "      <td>How might thalassemia be treated? The best tre...</td>\n",
       "      <td>How might thalassemia be treated? The best tre...</td>\n",
       "      <td>92</td>\n",
       "      <td>[How might thalassemia be treated?, The best t...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1000 rows Ã— 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               question  \\\n",
       "6490  What are the treatments for Progressive transf...   \n",
       "8609               How to diagnose Heart Palpitations ?   \n",
       "9978  What are the genetic changes related to mucopo...   \n",
       "8070      How to diagnose Parasites - Schistosomiasis ?   \n",
       "8577       Who is at risk for Iron-Deficiency Anemia? ?   \n",
       "...                                                 ...   \n",
       "5734             What causes Relapsing polychondritis ?   \n",
       "5191                      What is (are) Leprechaunism ?   \n",
       "5390  What are the treatments for Hallermann-Streiff...   \n",
       "860            What are the stages of Uterine Sarcoma ?   \n",
       "7270          What are the treatments for Thalassemia ?   \n",
       "\n",
       "                                                 answer  \\\n",
       "6490  What treatment is available for progressive tr...   \n",
       "8609  First, your doctor will want to find out wheth...   \n",
       "9978  Mutations in the ARSB gene cause MPS VI. The A...   \n",
       "8070  Stool or urine samples can be examined microsc...   \n",
       "8577  Infants and Young Children Infants and young c...   \n",
       "...                                                 ...   \n",
       "5734  What causes relapsing polychondritis? The exac...   \n",
       "5191  Leprechaunism is a congenital (present from bi...   \n",
       "5390  How might Hallermann-Streiff syndrome be treat...   \n",
       "860   Key Points - After uterine sarcoma has been di...   \n",
       "7270  How might thalassemia be treated? The best tre...   \n",
       "\n",
       "                                        complete_answer  answer_tokens  \\\n",
       "6490  What treatment is available for progressive tr...             96   \n",
       "8609  First, your doctor will want to find out wheth...            873   \n",
       "9978  Mutations in the ARSB gene cause MPS VI. The A...            220   \n",
       "8070  Stool or urine samples can be examined microsc...             81   \n",
       "8577  Infants and Young Children Infants and young c...            674   \n",
       "...                                                 ...            ...   \n",
       "5734  What causes relapsing polychondritis? The exac...            211   \n",
       "5191  Leprechaunism is a congenital (present from bi...             85   \n",
       "5390  How might Hallermann-Streiff syndrome be treat...            270   \n",
       "860   Key Points - After uterine sarcoma has been di...           1537   \n",
       "7270  How might thalassemia be treated? The best tre...             92   \n",
       "\n",
       "                                          answer_chunks  \n",
       "6490  [What treatment is available for progressive t...  \n",
       "8609  [First, your doctor will want to find out whet...  \n",
       "9978  [Mutations in the ARSB gene cause MPS VI. The ...  \n",
       "8070  [Stool or urine samples can be examined micros...  \n",
       "8577  [Infants and Young Children Infants and young ...  \n",
       "...                                                 ...  \n",
       "5734  [What causes relapsing polychondritis? The exa...  \n",
       "5191  [Leprechaunism is a congenital (present from b...  \n",
       "5390  [How might Hallermann-Streiff syndrome be trea...  \n",
       "860   [Key Points - After uterine sarcoma has been d...  \n",
       "7270  [How might thalassemia be treated?, The best t...  \n",
       "\n",
       "[1000 rows x 5 columns]"
      ]
     },
     "execution_count": 154,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 155,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>answer_chunks</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6490</th>\n",
       "      <td>What are the treatments for Progressive transf...</td>\n",
       "      <td>What treatment is available for progressive tr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6490</th>\n",
       "      <td>What are the treatments for Progressive transf...</td>\n",
       "      <td>Affected individuals should have regular follo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8609</th>\n",
       "      <td>How to diagnose Heart Palpitations ?</td>\n",
       "      <td>First, your doctor will want to find out wheth...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8609</th>\n",
       "      <td>How to diagnose Heart Palpitations ?</td>\n",
       "      <td>How often do they occur? Do they start and sto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8609</th>\n",
       "      <td>How to diagnose Heart Palpitations ?</td>\n",
       "      <td>Do they happen at a certain time of day? Your ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>860</th>\n",
       "      <td>What are the stages of Uterine Sarcoma ?</td>\n",
       "      <td>Uterine sarcoma may be diagnosed, staged, and ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>860</th>\n",
       "      <td>What are the stages of Uterine Sarcoma ?</td>\n",
       "      <td>Sometimes organs are removed or tissue samples...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>860</th>\n",
       "      <td>What are the stages of Uterine Sarcoma ?</td>\n",
       "      <td>For a regional lymphadenectomy, some of the ly...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7270</th>\n",
       "      <td>What are the treatments for Thalassemia ?</td>\n",
       "      <td>How might thalassemia be treated?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7270</th>\n",
       "      <td>What are the treatments for Thalassemia ?</td>\n",
       "      <td>The best treatment options depend on the sever...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2118 rows Ã— 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               question  \\\n",
       "6490  What are the treatments for Progressive transf...   \n",
       "6490  What are the treatments for Progressive transf...   \n",
       "8609               How to diagnose Heart Palpitations ?   \n",
       "8609               How to diagnose Heart Palpitations ?   \n",
       "8609               How to diagnose Heart Palpitations ?   \n",
       "...                                                 ...   \n",
       "860            What are the stages of Uterine Sarcoma ?   \n",
       "860            What are the stages of Uterine Sarcoma ?   \n",
       "860            What are the stages of Uterine Sarcoma ?   \n",
       "7270          What are the treatments for Thalassemia ?   \n",
       "7270          What are the treatments for Thalassemia ?   \n",
       "\n",
       "                                          answer_chunks  \n",
       "6490  What treatment is available for progressive tr...  \n",
       "6490  Affected individuals should have regular follo...  \n",
       "8609  First, your doctor will want to find out wheth...  \n",
       "8609  How often do they occur? Do they start and sto...  \n",
       "8609  Do they happen at a certain time of day? Your ...  \n",
       "...                                                 ...  \n",
       "860   Uterine sarcoma may be diagnosed, staged, and ...  \n",
       "860   Sometimes organs are removed or tissue samples...  \n",
       "860   For a regional lymphadenectomy, some of the ly...  \n",
       "7270                  How might thalassemia be treated?  \n",
       "7270  The best treatment options depend on the sever...  \n",
       "\n",
       "[2118 rows x 2 columns]"
      ]
     },
     "execution_count": 155,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train[[\"question\", \"answer_chunks\"]].explode(\"answer_chunks\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## RAG"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Vector Database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [],
   "source": [
    "loader = DataFrameLoader(train, page_content_column=\"question\")\n",
    "docs = loader.load()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=150, chunk_overlap=50)\n",
    "\n",
    "\n",
    "splits = text_splitter.split_documents(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:sentence_transformers.SentenceTransformer:Use pytorch device_name: cuda\n",
      "INFO:sentence_transformers.SentenceTransformer:Load pretrained SentenceTransformer: sentence-transformers/all-MiniLM-L6-v2\n",
      "INFO:faiss.loader:Loading faiss with AVX512 support.\n",
      "INFO:faiss.loader:Could not load library with AVX512 support due to:\n",
      "ModuleNotFoundError(\"No module named 'faiss.swigfaiss_avx512'\")\n",
      "INFO:faiss.loader:Loading faiss with AVX2 support.\n",
      "INFO:faiss.loader:Successfully loaded faiss with AVX2 support.\n"
     ]
    }
   ],
   "source": [
    "# embed = OllamaEmbeddings(model=\"llama3.2:3b\")\n",
    "embeddings_model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "\n",
    "\n",
    "embed = HuggingFaceEmbeddings(model_name=embeddings_model_name)\n",
    "\n",
    "\n",
    "vectorstore_questions = FAISS.from_documents(documents=splits, embedding=embed)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# LLM\n",
    "llm = ChatOllama(model=\"llama3.2:1b\", temperature=0)\n",
    "\n",
    "# Prompt\n",
    "system_message = \"\"\"\n",
    "You are a medical assistant AI Bot oriented by document search.\n",
    "You answer need to be based on the provivided context, you don't need to specify how you answer to the user.\n",
    "If you don't have certain about the answer, please let the user know and don't try to guess.\n",
    "\"\"\"\n",
    "\n",
    "prompt = \"\"\"\n",
    "Answer the provided question based on the retrieved documments.\n",
    "\n",
    "Question:\n",
    "{query}\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Answer:\n",
    "\"\"\"\n",
    "\n",
    "template = ChatPromptTemplate([(\"system\", system_message), (\"human\", prompt), a])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Define the flow"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.graph import START, StateGraph\n",
    "from typing_extensions import List, TypedDict\n",
    "from langchain_core.documents import Document\n",
    "from langchain\n",
    "\n",
    "import tiktoken\n",
    "\n",
    "tokenizer = tiktoken.get_encoding(\"o200k_base\")\n",
    "\n",
    "\n",
    "class State(TypedDict):\n",
    "    query: str\n",
    "    context: List[Document]\n",
    "    answer: str\n",
    "    threshold: float\n",
    "\n",
    "def multiquery(state: State):\n",
    "\n",
    "def retrieve(state: State):\n",
    "\n",
    "    retrieved_docs = vectorstore_questions.similarity_search_with_relevance_scores(\n",
    "        state[\"query\"], k=3\n",
    "    )\n",
    "\n",
    "    filtered_retrieved = list(\n",
    "        filter(lambda x: x[1] > state[\"threshold\"], retrieved_docs)\n",
    "    )\n",
    "\n",
    "    return {\"context\": filtered_retrieved}\n",
    "\n",
    "\n",
    "def generate(state: State):\n",
    "\n",
    "    docs_content = \"\\n\\n\".join(doc.metadata[\"answer\"] for doc in state[\"context\"])\n",
    "\n",
    "    messages = template.invoke({\"query\": state[\"query\"], \"context\": docs_content})\n",
    "\n",
    "    # print(\" ---------- PROMPT ----------\")\n",
    "    # for i in messages:\n",
    "    #     for j in i[1]:\n",
    "    #         print(j.content)\n",
    "    # print(\" ---------- PROMPT ----------\")\n",
    "\n",
    "    response = llm.invoke(messages)\n",
    "\n",
    "    return {\"answer\": response}\n",
    "\n",
    "\n",
    "graph_builder = StateGraph(State).add_sequence([retrieve, generate])\n",
    "graph_builder.add_edge(START, \"retrieve\")\n",
    "graph = graph_builder.compile()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from IPython.display import Image, display\n",
    "\n",
    "try:\n",
    "    display(Image(graph.get_graph().draw_mermaid_png()))\n",
    "except Exception:\n",
    "    # This requires some extra dependencies and is optional\n",
    "    pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What are the symptoms of Juvenile osteoporosis ?\n",
      "\n",
      "True Answer: What are the signs and symptoms of Juvenile osteoporosis? The Human Phenotype Ontology provides the following list of signs and symptoms for Juvenile osteoporosis. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Bone pain 90% Recurrent fractures 90% Reduced bone mineral density 90% Gait disturbance 50% Kyphosis 7.5% Autosomal recessive inheritance - Low serum calcitriol (1,25-dihydroxycholecalciferol) - Osteoporosis - The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.\n",
      "\n",
      "Model Answer: \n",
      "The signs and symptoms of Juvenile osteoporosis include:\n",
      "\n",
      "1. Bone pain\n",
      "2. Recurrent fractures\n",
      "3. Reduced bone mineral density\n",
      "4. Gait disturbance\n",
      "5. Kyphosis\n",
      "6. Autosomal recessive inheritance\n",
      "7. Low serum calcitriol (1,25-dihydroxycholecalciferol)\n",
      "8. Osteoporosis\n"
     ]
    }
   ],
   "source": [
    "question = train.iloc[0].question\n",
    "answer = train.iloc[0].answer\n",
    "\n",
    "print(f\"Question: {question}\\n\")\n",
    "print(f\"True Answer: {answer}\\n\")\n",
    "\n",
    "inference = graph.invoke({\"query\": question, \"thershold\": 0.7})\n",
    "\n",
    "print(f\"Model Answer: \\n{inference['answer'].content}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "31317ece012b4dba80194d26a72972e5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/185 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for i, row in tqdm(test.iterrows(), total=test.shape[0]):\n",
    "    question = row.question\n",
    "    answer = row.answer\n",
    "\n",
    "    inference = graph.invoke(\n",
    "        {\n",
    "            \"query\": question,\n",
    "        }\n",
    "    )\n",
    "\n",
    "    test.loc[i, \"model_answer\"] = inference[\"answer\"].content\n",
    "    test.loc[i, \"generation_duration\"] = inference[\"answer\"].response_metadata[\n",
    "        \"total_duration\"\n",
    "    ]\n",
    "    test.loc[i, \"generation_n_tokens\"] = inference[\"answer\"].response_metadata[\n",
    "        \"eval_count\"\n",
    "    ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "metrics = compute_metrics(\n",
    "    test[\"model_answer\"].tolist(), [[i] for i in test[\"answer\"].tolist()]\n",
    ")\n",
    "\n",
    "\n",
    "metrics[\"mean_generation_duration\"] = test[\"generation_duration\"].mean() * 1e-9\n",
    "\n",
    "\n",
    "metrics[\"mean_generation_n_tokens\"] = test[\"generation_n_tokens\"].mean()\n",
    "\n",
    "\n",
    "metrics[\"bleu_score\"] = metrics[\"bleu\"][\"bleu\"]\n",
    "\n",
    "\n",
    "metrics[\"bertscore_precision\"] = np.mean(metrics[\"bertscore\"][\"precision\"])\n",
    "\n",
    "metrics[\"bertscore_recall\"] = np.mean(metrics[\"bertscore\"][\"recall\"])\n",
    "\n",
    "\n",
    "metrics[\"bertscore_f1\"] = np.mean(metrics[\"bertscore\"][\"f1\"])\n",
    "\n",
    "metrics[\"st_similarities\"] = np.mean(metrics[\"st_similarities\"])\n",
    "\n",
    "\n",
    "del metrics[\"bleu\"]\n",
    "\n",
    "\n",
    "del metrics[\"bertscore\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'st_similarities': np.float32(0.893341),\n",
       " 'mean_generation_duration': np.float64(1.2321680394594596),\n",
       " 'mean_generation_n_tokens': np.float64(105.52972972972972),\n",
       " 'bleu_score': 0.014881583553857566,\n",
       " 'bertscore_precision': np.float64(0.7898838935671626),\n",
       " 'bertscore_recall': np.float64(0.740426673438098),\n",
       " 'bertscore_f1': np.float64(0.7622926318967664)}"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "metrics_csv = pd.DataFrame(metrics, index=[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>st_similarities</th>\n",
       "      <th>mean_generation_duration</th>\n",
       "      <th>mean_generation_n_tokens</th>\n",
       "      <th>bleu_score</th>\n",
       "      <th>bertscore_precision</th>\n",
       "      <th>bertscore_recall</th>\n",
       "      <th>bertscore_f1</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.893341</td>\n",
       "      <td>1.232168</td>\n",
       "      <td>105.52973</td>\n",
       "      <td>0.014882</td>\n",
       "      <td>0.789884</td>\n",
       "      <td>0.740427</td>\n",
       "      <td>0.762293</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   st_similarities  mean_generation_duration  mean_generation_n_tokens  \\\n",
       "1         0.893341                  1.232168                 105.52973   \n",
       "\n",
       "   bleu_score  bertscore_precision  bertscore_recall  bertscore_f1  \n",
       "1    0.014882             0.789884          0.740427      0.762293  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "metrics_csv"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "metrics_csv.to_csv(\n",
    "    f\"../results/metrics_rag_{llm.model.replace(':','_')}.csv\", index=False\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "test.to_csv(f\"../results/test_rag_{llm.model.replace(':','_')}.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "</style>\n",
       "<table id=\"T_1be1b\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_1be1b_level0_col0\" class=\"col_heading level0 col0\" >question</th>\n",
       "      <th id=\"T_1be1b_level0_col1\" class=\"col_heading level0 col1\" >answer</th>\n",
       "      <th id=\"T_1be1b_level0_col2\" class=\"col_heading level0 col2\" >model_answer</th>\n",
       "      <th id=\"T_1be1b_level0_col3\" class=\"col_heading level0 col3\" >generation_duration</th>\n",
       "      <th id=\"T_1be1b_level0_col4\" class=\"col_heading level0 col4\" >generation_n_tokens</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_1be1b_level0_row0\" class=\"row_heading level0 row0\" >6890</th>\n",
       "      <td id=\"T_1be1b_row0_col0\" class=\"data row0 col0\" >What are the treatments for Filippi syndrome ?</td>\n",
       "      <td id=\"T_1be1b_row0_col1\" class=\"data row0 col1\" >How might Filippi syndrome be treated? The treatment of Filippi syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of medical professionals who may need to systematically and comprehensively plan an affected child's treatment. These professionals may include pediatricians; physicians who specialize in disorders of the skeleton, joints, muscles, and related tissues (orthopedists); and/or other health care professionals. In some affected individuals, treatment may include surgical repair of certain skeletal or other abnormalities associated with the disorder. The surgical procedures performed will depend upon the severity of the abnormalities, their associated symptoms, and other factors.</td>\n",
       "      <td id=\"T_1be1b_row0_col2\" class=\"data row0 col2\" >The treatments for Filippi syndrome are:\n",
       "\n",
       "1. Low-dose aspirin\n",
       "2. Warfarin (for individuals who have already had a stroke or experience recurrent clots)\n",
       "\n",
       "The recommended treatment for Peters plus syndrome is:\n",
       "\n",
       "1. Eye examination\n",
       "2. Growth hormone testing\n",
       "3. Developmental assessment\n",
       "4. Regular developmental assessments\n",
       "5. Agents like corticosteroids should be avoided.\n",
       "\n",
       "For Poland syndrome, the treatments may include:\n",
       "\n",
       "1. Surgical correction of chest wall deformities (e.g., to improve appearance)\n",
       "2. Breast reconstruction in females (at the time of normal full breast development)</td>\n",
       "      <td id=\"T_1be1b_row0_col3\" class=\"data row0 col3\" >1202936400.000000</td>\n",
       "      <td id=\"T_1be1b_row0_col4\" class=\"data row0 col4\" >123.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1be1b_level0_row1\" class=\"row_heading level0 row1\" >2666</th>\n",
       "      <td id=\"T_1be1b_row1_col0\" class=\"data row1 col0\" >What is (are) Kluver Bucy syndrome ?</td>\n",
       "      <td id=\"T_1be1b_row1_col1\" class=\"data row1 col1\" >Kluver Bucy syndrome is a rare behavioral impairment characterized by inappropriate sexual behaviors and mouthing of objects. Other signs and symptoms, include a diminished ability to visually recognize objects, loss of normal fear and anger responses, memory loss, distractibility, seizures, and dementia. It is associated with damage to the anterior temporal lobes of the brain. Cases have been reported in association with herpes encephalitis and head trauma. Treatment is symptomatic and may include the use of psychotropic medications.</td>\n",
       "      <td id=\"T_1be1b_row1_col2\" class=\"data row1 col2\" >Kluver-Bucy syndrome</td>\n",
       "      <td id=\"T_1be1b_row1_col3\" class=\"data row1 col3\" >276067300.000000</td>\n",
       "      <td id=\"T_1be1b_row1_col4\" class=\"data row1 col4\" >8.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1be1b_level0_row2\" class=\"row_heading level0 row2\" >6494</th>\n",
       "      <td id=\"T_1be1b_row2_col0\" class=\"data row2 col0\" >What is (are) Chromosome 4q deletion ?</td>\n",
       "      <td id=\"T_1be1b_row2_col1\" class=\"data row2 col1\" >Chromosome 4q deletion is a chromosome abnormality that affects many different parts of the body. People with this condition are missing genetic material located on the long arm (q) of chromosome 4 in each cell. The severity of the condition and the associated signs and symptoms vary based on the size and location of the deletion and which genes are involved. Common features shared by many people with this deletion include distinctive craniofacial features, skeletal abnormalities, heart defects, intellectual disability, developmental delay, and short stature. Most cases are not inherited, although affected people can pass the deletion on to their children. Treatment is based on the signs and symptoms present in each person.</td>\n",
       "      <td id=\"T_1be1b_row2_col2\" class=\"data row2 col2\" >Chromosome 4q deletion is not mentioned in the provided text.</td>\n",
       "      <td id=\"T_1be1b_row2_col3\" class=\"data row2 col3\" >359862600.000000</td>\n",
       "      <td id=\"T_1be1b_row2_col4\" class=\"data row2 col4\" >15.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1be1b_level0_row3\" class=\"row_heading level0 row3\" >16155</th>\n",
       "      <td id=\"T_1be1b_row3_col0\" class=\"data row3 col0\" >What causes Hypothyroidism ?</td>\n",
       "      <td id=\"T_1be1b_row3_col1\" class=\"data row3 col1\" >Hypothyroidism has several causes, including - Hashimotos disease - thyroiditis, or inflammation of the thyroid - congenital hypothyroidism, or hypothyroidism that is present at birth - surgical removal of part or all of the thyroid - radiation treatment of the thyroid - some medications Less commonly, hypothyroidism is caused by too much or too little iodine in the diet or by abnormalities of the pituitary gland. Hashimotos Disease Hashimotos disease, also called chronic lymphocytic thyroiditis, is the most common cause of hypothyroidism in the United States.1 Hashimotos disease is a form of chronic inflammation of the thyroid gland. Hashimotos disease is also an autoimmune disorder. Normally, the immune system protects the body against foreign invaderssuch as viruses and bacteriathat can cause illness. But in autoimmune diseases, the immune system attacks the bodys own cells and organs. With Hashimotos disease, the immune system attacks the thyroid, causing inflammation and interfering with its ability to produce thyroid hormones. More information is provided in the NIDDK health topic, Hashimotos Disease. Thyroiditis Thyroiditis causes stored thyroid hormone to leak out of the thyroid gland. At first, the leakage raises hormone levels in the blood, leading to hyperthyroidismwhen thyroid hormone levels are too highthat lasts for 1 or 2 months. Most people then develop hypothyroidism before the thyroid is completely healed. Several types of thyroiditis can cause hyperthyroidism followed by hypothyroidism: - Subacute thyroiditis. This condition involves painful inflammation and enlargement of the thyroid. Experts are not sure what causes subacute thyroiditis, but it may be related to a viral or bacterial infection. The condition usually goes away on its own in a few months. - Postpartum thyroiditis. This type of thyroiditis develops after a woman gives birth. For more information, see the section titled What happens with pregnancy and thyroid conditions? - Silent thyroiditis. This type of thyroiditis is called silent because it is painless, as is postpartum thyroiditis, even though the thyroid may be enlarged. Like postpartum thyroiditis, silent thyroiditis is probably an autoimmune condition and sometimes develops into permanent hypothyroidism. Congenital Hypothyroidism Some babies are born with a thyroid that is not fully developed or does not function properly. If untreated, congenital hypothyroidism can lead to mental retardation and growth failure. Early treatment can prevent these complications, so most newborns in the United States are screened for hypothyroidism. Surgical Removal of the Thyroid When part of the thyroid is removed, the remaining part may produce normal amounts of thyroid hormone, but some people who have this surgery develop hypothyroidism. Removal of the entire thyroid always results in hypothyroidism. Part or all of the thyroid may be surgically removed as a treatment for - hyperthyroidism - a large goiter, which is an enlarged thyroid that may cause the neck to appear swollen and can interfere with normal breathing and swallowing - thyroid nodules, which are noncancerous tumors, called adenomas, or lumps in the thyroid that can produce excess thyroid hormone - thyroid cancer Radiation Treatment of the Thyroid Radioactive iodine, a common treatment for hyperthyroidism, gradually destroys the cells of the thyroid. Most people who receive radioactive iodine treatment eventually develop hypothyroidism. People with Hodgkins disease, other lymphomas, and head or neck cancers are treated with radiation, which can also damage the thyroid. Medications Some drugs can interfere with thyroid hormone production and lead to hypothyroidism, including - amiodarone, a heart medication - interferon alpha, a cancer medication - lithium, a bipolar disorder medication - interleukin-2, a kidney cancer medication</td>\n",
       "      <td id=\"T_1be1b_row3_col2\" class=\"data row3 col2\" >Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormones, which are essential for regulating various bodily functions such as metabolism, heart rate, and energy production. The exact cause of hypothyroidism can be complex and multifactorial, but some common underlying factors include:\n",
       "\n",
       "* Genetics: As mentioned in the provided text, Pseudopseudohypoparathyroidism (PPHP) is an inherited condition that affects the GNAS gene, leading to thyroid problems.\n",
       "* Autoimmune disorders: Some autoimmune conditions, such as Hashimoto's disease, can cause hypothyroidism by attacking and destroying the thyroid gland.\n",
       "* Thyroiditis: Inflammation of the thyroid gland can lead to hypothyroidism.\n",
       "* Other medical conditions: Certain medical conditions, such as hyperthyroidism or thyroid cancer, can also cause hypothyroidism.\n",
       "\n",
       "It's worth noting that hypothyroidism is often diagnosed based on a combination of symptoms and laboratory tests, including:\n",
       "\n",
       "* TSH test\n",
       "* Ultrasensitive TSH test\n",
       "* T4 test\n",
       "* Thyroid autoantibody test\n",
       "\n",
       "These tests help healthcare providers to confirm the diagnosis and determine the underlying cause of hypothyroidism.</td>\n",
       "      <td id=\"T_1be1b_row3_col3\" class=\"data row3 col3\" >2398509700.000000</td>\n",
       "      <td id=\"T_1be1b_row3_col4\" class=\"data row3 col4\" >251.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1be1b_level0_row4\" class=\"row_heading level0 row4\" >9320</th>\n",
       "      <td id=\"T_1be1b_row4_col0\" class=\"data row4 col0\" >What is the outlook for Multifocal Motor Neuropathy ?</td>\n",
       "      <td id=\"T_1be1b_row4_col1\" class=\"data row4 col1\" >Improvement in muscle strength usually begins within 3 to 6 weeks after treatment is started. Most patients who receive treatment early experience little, if any, disability. However, there is evidence of slow progression over many years.</td>\n",
       "      <td id=\"T_1be1b_row4_col2\" class=\"data row4 col2\" >The outlook for Multifocal Motor Neuropathy (MMN) is generally mild, but it can be severe in some cases. While there is no cure for MMN, various treatments and management strategies can help alleviate symptoms and improve quality of life.</td>\n",
       "      <td id=\"T_1be1b_row4_col3\" class=\"data row4 col3\" >540603000.000000</td>\n",
       "      <td id=\"T_1be1b_row4_col4\" class=\"data row4 col4\" >52.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x2111e543310>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test.head(5).style"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "ml_base_310",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
